

Christian Hampp

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2919297/publications.pdf>

Version: 2024-02-01

44
papers

1,190
citations

393982

19
h-index

377514

34
g-index

45
all docs

45
docs citations

45
times ranked

1860
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of Antidiabetic Drugs in the U.S., 2003â€“2012. Diabetes Care, 2014, 37, 1367-1374.	4.3	179
2	Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs. Annals of Internal Medicine, 2016, 164, 705.	2.0	91
3	Use of Prescription Antiobesity Drugs in the United States. Pharmacotherapy, 2013, 33, 1299-1307.	1.2	89
4	Cancer Risk Associated with Lorcaserin â€” The FDAâ€™s Review of the CAMELLIA-TIMI 61 Trial. New England Journal of Medicine, 2020, 383, 1000-1002.	13.9	88
5	Cost-effectiveness of Respiratory Syncytial Virus Prophylaxis in Various Indications. JAMA Pediatrics, 2011, 165, 498.	3.6	75
6	Emergency Hospitalizations for Unsupervised Prescription Medication Ingestions by Young Children. Pediatrics, 2014, 134, e1009-e1016.	1.0	69
7	Cost-Utility Analysis of Rimonabant in the Treatment of Obesity. Value in Health, 2008, 11, 389-399.	0.1	53
8	Appropriateness of Age Thresholds for Respiratory Syncytial Virus Immunoprophylaxis in Moderate-Preterm Infants. JAMA Pediatrics, 2013, 167, 1118.	3.3	50
9	Use of Sodiumâ€“Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis. Diabetes Care, 2020, 43, 90-97.	4.3	36
10	A systematic review of pregnancy exposure registries: examination of protocol-specified pregnancy outcomes, target sample size, and comparator selection. Pharmacoepidemiology and Drug Safety, 2017, 26, 208-214.	0.9	35
11	Data linkage in pharmacoepidemiology: A call for rigorous evaluation and reporting. Pharmacoepidemiology and Drug Safety, 2020, 29, 9-17.	0.9	34
12	Sentinel Modular Program for Propensity Scoreâ€“Matched Cohort Analyses. Epidemiology, 2017, 28, 838-846.	1.2	32
13	Palivizumab Utilization and Compliance: Trends in Respiratory Syncytial Virus Prophylaxis in Florida. Journal of Pediatrics, 2010, 156, 953-959.e1.	0.9	27
14	<i>Notes from the Field:</i> Pediatric Emergency Department Visits for Buprenorphine/Naloxone Ingestion â€” United States, 2008â€“2015. Morbidity and Mortality Weekly Report, 2016, 65, 1148-1149.	9.0	24
15	Prevalence, Trends, and Patterns of Use of Antidiabetic Medications Among Pregnant Women, 2001-2007. Obstetrics and Gynecology, 2013, 121, 106-114.	1.2	22
16	Patient understanding of drug risks: an evaluation of medication guide assessments. Pharmacoepidemiology and Drug Safety, 2015, 24, 518-525.	0.9	22
17	An algorithm to identify preterm infants in administrative claims data. Pharmacoepidemiology and Drug Safety, 2012, 21, 640-650.	0.9	21
18	Pioglitazone and bladder cancer: FDA's assessment. Pharmacoepidemiology and Drug Safety, 2017, 26, 117-118.	0.9	21

#	ARTICLE	IF	CITATIONS
19	Prospective Postmarketing Surveillance of Acute Myocardial Infarction in New Users of Saxagliptin: A Population-Based Study. <i>Diabetes Care</i> , 2018, 41, 39-48.	4.3	21
20	Review of A Large Clinical Series: Once- Versus Twice-Daily Enoxaparin for Venous Thromboembolism Prophylaxis in High-Risk Trauma Patients. <i>Journal of Intensive Care Medicine</i> , 2011, 26, 111-115.	1.3	20
21	Enrollment and Retention in 34 United States Pregnancy Registries Contrasted with the Manufacturer's Capture of Spontaneous Reports for Exposed Pregnancies. <i>Drug Safety</i> , 2018, 41, 87-94.	1.4	18
22	Longitudinal Study of Optic Cup Progression in Children. <i>Journal of Pediatric Ophthalmology and Strabismus</i> , 2011, 48, 151-156.	0.3	18
23	Invasive Fungal Infections in Lung Transplant Recipients Not Receiving Routine Systemic Antifungal Prophylaxis: 12-Year Experience at a University Lung Transplant Center. <i>Pharmacotherapy</i> , 2011, 31, 537-545.	1.2	17
24	Effectiveness of palivizumab prophylaxis in infants and children in Florida. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 53-60.	0.9	15
25	Feasibility of Short-Term Infusion of Magnesium Sulfate in Pediatric Patients With Status Asthmaticus. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , 2012, 17, 150-154.	0.3	15
26	Validation of algorithms to estimate gestational age at birth in the Medicaid Analytic eXtract—Quantifying the misclassification of maternal drug exposure during pregnancy. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1414-1422.	0.9	14
27	Utilization of drugs with pregnancy exposure registries during pregnancy. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 604-611.	0.9	11
28	Use of Prescription Drug Samples in the USA: A Descriptive Study with Considerations for Pharmacoepidemiology. <i>Drug Safety</i> , 2016, 39, 261-270.	1.4	10
29	Safety assessment of niacin in the US Food and Drug Administration's mini-sentinel system. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 30-37.	0.9	10
30	Misclassification in Assessment of First Trimester In-utero Exposure to Drugs Used Proximally to Conception: the Example of Letrozole Utilization for Infertility Treatment. <i>American Journal of Epidemiology</i> , 2019, 188, 418-425.	1.6	10
31	Validity of Laboratory-based Surveillance for Detection of Respiratory Syncytial Virus Seasons. <i>American Journal of Epidemiology</i> , 2013, 177, 841-851.	1.6	9
32	Validation of mother-infant linkage using Medicaid Case ID variable within the Medicaid Analytic eXtract (MAX) database. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 1222-1230.	0.9	8
33	The Role of Unit-Dose Child-Resistant Packaging in Unintentional Childhood Exposures to Buprenorphine-Naloxone Tablets. <i>Drug Safety</i> , 2020, 43, 189-191.	1.4	5
34	Recommendations on the use and nonuse of the p value in biomedical research. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, 1262-1266.	0.5	4
35	Evaluation of the US Food and Drug Administration Sentinel Analysis Tools Using a Comparator with a Different Indication: Comparing the Rates of Gastrointestinal Bleeding in Warfarin and Statin Users. <i>Pharmaceutical Medicine</i> , 2019, 33, 29-43.	1.0	4
36	Root cause analysis and subsequent intervention to improve first dose antibiotic turnaround time for hospitalized pediatric patients. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , 2010, 15, 182-8.	0.3	3

#	ARTICLE	IF	CITATIONS
37	Small Budget Impact Is a Result of Flawed Assumptions and Ignores Questionable Cost-Effectiveness for RSV Prophylaxis. <i>Value in Health</i> , 2010, 13, 684.	0.1	2
38	<i>Editorial Commentary</i> : Can a Reduced-Dose Prophylaxis Schedule Provide Adequate Coverage Against Respiratory Syncytial Virus Infection?. <i>Clinical Infectious Diseases</i> , 2015, 61, 515-516.	2.9	2
39	Usability of encounter data for Medicaid comprehensive managed care vs traditional Medicaid fee-for-service claims among pregnant women. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 30-38.	0.9	2
40	Calibration of Chronic Lung Disease Severity as a Risk Factor for Respiratory Syncytial Virus Hospitalization. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 317-325.	0.6	2
41	Methodological Concerns Regarding Cost-effectiveness Analysis of Palivizumab in Florida Medicaidâ€”Reply. <i>JAMA Pediatrics</i> , 2012, 166, 968.	3.6	1
42	Response to Respiratory Syncytial Virus. <i>Southern Medical Journal</i> , 2008, 101, 212-213.	0.3	1
43	Longitudinal study of optic cup progression in children. <i>Journal of AAPOS</i> , 2010, 14, e24-e25.	0.2	0
44	Utilization of chronic lung disease treatment before the respiratory syncytial virus season as palivizumab prophylaxis qualifier in the American Academy of Pediatrics Guidelines. <i>European Journal of Pediatrics</i> , 2022, 181, 841-845.	1.3	0